This content is PDF only. Please click on the PDF icon to access.
The opening 10 chapters cover general considerations, such as design, statistical and epidemiologic considerations in design, parties with interests in trials (the patient, the investigator, the clinical or coordinating center, the Food and Drug Administration, and the pharmaceutical and insurance industries). The remaining 15 chapters critically survey trials in a large number of diseases (for example, cerebrovascular disease, epilepsy, headache, and myasthenia gravis), with particular attention to designs, outcome-measurement methods, statistical treatments, population samples, and outcomes. There is content here likely to have substantial value for investigators conducting clinical trials in cardiovascular medicine, oncology, and other fields of internal medicine.
Controlled Trials in Neurological Disease. Ann Intern Med. 1991;115:74. doi: https://doi.org/10.7326/0003-4819-115-1-74_8
Download citation file:
Published: Ann Intern Med. 1991;115(1):74.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use